RSNA 2017: FDA clears MIM Software’s post-treatment dosimetry of Y90 microspheres

MIM Software, a Cleveland-headquartered global provider of medical imaging software, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for post-treatment dosimetry of Yttrium-90 (Y90) microspheres.

Yttrium-90 microspheres deliver local radiation as permanent brachytherapy implants to tumors in the liver. Currently, PET or SPECT images are obtained after treatment to verify the distribution of microspheres. Now, absorbed dose from the Y90 microspheres can be calculated on a voxel-by-voxel basis using the PET or SPECT images.

MIM SurePlan™ LiverY90 provides timesaving tools for liver and tumor segmentation, deformable registration, and allows patient-specific dose calculation on Y90 PET and Bremsstrahlung SPECT images after administration of permanent Y90 microsphere implants. The absorbed dose can be calculated for tumors and the liver to help provide important additional information to the clinician.

Three methods are available for dose calculation: Local Deposition Model, Local Deposition Model with scaling for known injected activity, and the Voxel S Value approach based on the schema in MIRD Pamphlet No. 17. All three methods are available for PET while only the Local Deposition Model with scaling for known activity is available for SPECT images that are not in Becquerel per milliliter (Bq/ml).